Revlimid

Quick orientation

Revlimid (lenalidomide) is an oral immunomodulatory imide drug (IMiD) developed by Bristol Myers Squibb (Celgene). The US Food and Drug Administration first approved Revlimid in December 2005 for transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with deletion 5q, and has since approved Revlimid for multiple myeloma, mantle cell lymphoma after at least two prior therapies, previously treated follicular lymphoma, and previously treated marginal zone lymphoma in combination with rituximab. The drug is given as a once-daily oral capsule with dose and cycle length determined by indication, typically 10 mg or 25 mg in multiple myeloma. Revlimid is dispensed under the Revlimid REMS programme due to embryo-fetal toxicity risk.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

How Reserve Meds coordinates Revlimid

1. Patient or treating physician submits an intake at the patient portal.
2. Reserve Meds clinical team verifies appropriateness for the patient and destination country.
3. Treating physician issues prescription and clinical justification.
4. Country-specific named-patient documentation is prepared.
5. Revlimid is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
6. Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.

Access by country

Reserve Meds publishes a detailed country access guide for Revlimid in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.

Start a request for Revlimid

Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.

Start your case Or message us on WhatsApp